Connect Biopharma Holdings

CNTB · NASDAQ

$0.8752−$0.0246 (−2.73%)TodayMarket closed · Oct 20, 7:56 PM ET

Prev close $0.8998

About CNTB

Connect Biopharma Holdings Ltd. operates as clinical-stage biopharmaceutical company. The company is headquartered in San Diego, California and currently employs 64 full-time employees. The company went IPO on 2021-03-19. The firm is focused on advancing rademikibart, a potentially best-in-class next generation anti-interleukin-4-receptor alpha (IL-4Rα) antibody, to transform acute and chronic care in asthma and chronic obstructive pulmonary disease (COPD). Its lead product candidate, rademikibart, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) in development for the treatment of atopic dermatitis (AD) and asthma. As an inhibitor of IL-4Rα, rademikibart blocks inflammatory signaling by both IL-4 and IL-13. The firm has completed a global Phase II trial (CBP-201-WW001) of rademikibart in adult patients with moderate-to-severe AD.

Employees: 64
Headquarters: San Diego, California
Listed: Mar 19, 2021
Sector: Health Care
Industry: Biotechnology
Website: connectbiopharm.com

Leadership

Connect Biopharma Holdings executives
Name	Title	Since	Age
Kleanthis Xanthopoulos	—	—	66
David Szekeres	—	—	51
Barry Quart	—	2024	68
Kimberly Manhard	—	—	65
Lisa Peraza	—	—	48
Raul Collazo	—	—	58
Lei Sun	—	—	61
Jeff Cohn	—	—	43
James Schoeneck	—	—	67
James Huang	—	—	59
Jean Liu	—	—	56
Karen Wilson	—	—	62

Similar companies

Companies in the same industry as Connect Biopharma Holdings

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.